Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity

European Journal of Cancer

Volumn 55, Issue , 2016, Pages 111-121

  Eggermont, Alexander M M ^a   Suciu, Stefan ^b   Rutkowski, Piotr ^c   Kruit, Willem H ^d   Punt, Cornelis J ^e   Dummer, Reinhard ^f   Salès, François ^g   Keilholz, Ulrich ^h   De Schaetzen, Gaetan ^b   Testori, Alessandro ⁱ  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b EORTC DATA CENTER   (Belgium)

^c INSTITUTE OF ONCOLOGY   (Poland)

^d ERASMUS MC CANCER INSTITUTE   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g JULES BORDET INSTITUTE   (Belgium)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Adjuvant; Interferon; Melanoma; Predictive factors; Randomised trial; Ulceration

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CUTANEOUS MELANOMA; DISTANT METASTASIS FREE SURVIVAL; DRUG SENSITIVITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; YOUNG ADULT; ADJUVANT CHEMOTHERAPY; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SECONDARY; SKIN NEOPLASMS; SKIN ULCER; TIME FACTOR; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RECOMBINANT PROTEINS; SKIN NEOPLASMS; SKIN ULCER; TIME FACTORS; TREATMENT OUTCOME;

EID: 84954458766     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.11.014     Document Type: Article

References (24)

1. A.M.M. Eggermont, A. Spatz, and C. Robert Cutaneous melanoma Lancet 383 2014 816 827
2. C.M. Balch, J.E. Gershenwald, S.-J. Soong, and et al. Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
3. C.M. Balch, J.E. Gershenwald, S.-J. Soong, and et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases J Clin Oncol 28 2010 2452 2459
4. E. Romano, M. Scordo, S.W. Dusza, D.G. Coit, and P.B. Chapman Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines J Clin Oncol 28 2010 3042 3047
5. A.C.J. Van Akkooi, Z.I. Nowecki, C. Voit, and et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes Ann Surg 248 2008 949 955
6. A.P.T. Van der Ploeg, A.C.J. Van Akkooi, P. Rutkowski, and et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria J Clin Oncol 29 2011 2206 2214
7. A.P. Van der Ploeg, A.C. van Akkooi, L.E. Haydu, and et al. The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients Eur J Cancer 50 2014 111 120
8. K. Wheatley, N. Ives, B. Hancock, M. Gore, A. Eggermont, and S. Suciu Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials Cancer Treat Rev 29 2003 241 252
9. S. Mocellin, S. Pasquali, C.R. Rossi, and D. Nitti Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis J Natl Cancer Inst 102 2010 493 501
10. S. Suciu, N. Ives, A.M. Eggermont, and et al. Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): an individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts) J Clin Oncol 32 5s 2014 [abstract 9067]
11. A.M.M. Eggermont, S. Suciu, R. MacKie, and et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial Lancet 366 2005 1189 1196
12. A.M.M. Eggermont, S. Suciu, M. Santinami, and et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial Lancet 372 2008 117 126
13. A.M. Eggermont, S. Suciu, A. Testori, and et al. Long term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma J Clin Oncol 30 2012 3810 3818
14. A.M.M. Eggermont, S. Suciu, A. Testori, and et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991 Eur J Cancer 48 2012 218 225
15. L.S. Freedman, and S.J. White On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial Biometrics 32 1976 691 694
16. EAST-3. Cytel Software Corporation. Cambridge, MA, USA.
17. J.D. Kalbfleisch, and R.L. Prentice The survival analysis of failure time data 2nd ed. 2002 Wiley Series in Probabilities and Statistics. Wiley Inter-Science New-Jersey, USA
18. A.M. Eggermont, A. Spatz, V. Lazar, and C. Robert Is ulceration in cutaneous melanoma just a prognostic and predictive factor or is ulcerated melanoma a distinct biologic entity? Curr Opin Oncol 24 2012 137 140
19. A. Spatz, M.G. Cook, D.E. Elder, M. Piepkorn, D.J. Ruiter, and R.L. Barnhill Interobserver reproducibility of ulceration assessment in primary cutaneous melanomas Eur J Cancer 39 2003 1861 1865
20. V. Winnepenninckx, V. Lazar, S. Michiels, and et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome J Natl Cancer Inst 98 2006 472 482
21. Z. Rakosy, S. Ecsedi, R. Toth, and et al. Integrative genomics identifies gene signature associated with melanoma ulceration PLoS One 8 1 2013 e54958
22. B. Elliott, R.A. Scolyer, S. Suciu, and et al. Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma Clin Cancer Res 13 2007 3825 3830
23. A.M. Eggermont, M. Maio, and C. Robert Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies Semin Oncol 42 2015 429 435
24. A.M. Eggermont, V. Chiarion-Sileni, J.J. Grob, and et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial Lancet Oncol 16 2015 522 530